Clinical Trial Opportunities in India Report

May 6, 2023

A joint report titled “Clinical Trial Opportunities in India” Report was released recently by the PwC India and US-India Chamber of Commerce (USAIC).

Clinical trial activity in India was historically low until 2014 due to unfavourable policies.
Currently, India is emerging as a favourable destination for conducting clinical trials due to regulatory reforms since 2013 and the New Drugs and Clinical Trial Rules of 2019. These measures have streamlined the approval processes, reducing timelines 30-40%.
Although India has contributed only approximately 4% to the global clinical trials on an annual basis since 2010, its clinical trial activity has been consistently rising since 2014 because of regulatory harmonization, which has permitted unrestricted entry to clinical trials within the country.
India’s diverse population and developing healthcare infrastructure create a conducive environment for clinical trials to succeed.
The Covid-19 pandemic has also contributed to raising awareness about the importance of clinical trials in India.
Among the top 20 pharma companies, AstraZeneca, Novartis, Eli Lilly, Pfizer, and J&J are the top sponsors of clinical trials in India, according to the report.